Early Remdesivir Tracked with About 25 Percent Lower Death Risk in Hospitalized Patients with Kidney Disease

A claims-based study of 27,000 hospitalized COVID patients links early remdesivir to lower 28-day death risk. Gilead helped conduct the research.

Have A Referral?